Skip to main content

Chong Kun Dang Holdings Corp. (001630.KS)

KSC Healthcare Drug Manufacturers - Specialty & GenericView data quality →
57.8Fair

ValueMarkers Composite Index

Top 67%#14,596 of 44,714
Undervalued

88% below intrinsic value ($269)

UndervaluedFair ValueOvervalued
Piotroski
6/9
Neutral
Beneish
-2.75
Low Risk
Altman
1.20
Distress
DCF Value
$269
Undervalued
ROIC
3.3%
Low
P/E
3.7
Value
Updated: ·Source: Data sourced from SEC filings and institutional providers. Not financial advice.·Report data issue

Chong Kun Dang Holdings Corp. (001630.KS) — VMCI valuation read

Chong Kun Dang Holdings Corp. (001630.KS) carries a VMCI composite of 58/100, 8 points above the Healthcare sector median of 50. Among mid-cap names, that gap places 001630.KS in the top third on the five-pillar weighting (Value 35%, Quality 30%, Integrity 15%, Growth 12%, Risk 8%).

The 001630.KS insider tape has been silent for the past 30 days on Form 4. Where executives neither buy nor sell, the bull and bear cases lean harder on filings cadence and the next earnings line.

**Investor frame.** Value reads 001630.KS trades at 14.0x earnings, 22% below the Healthcare median of 18.0x, which compresses or extends through the 11.0x EV/EBITDA versus a Healthcare 12.0x. Quality: ROIC of 14.0% sits 4.0pp above the Healthcare median (10.0%). Risk: net debt to EBITDA of 0.8x leaves covenant headroom, the line to track on Chong Kun Dang Holdings Corp.'s next 10-Q.

001630.KS fell 1.6% over the trailing 7 days, with a -3.7% read on a 30-day basis.

Chong Kun Dang Holdings Corp. manufactures and distributes pharmaceutical products in South Korea and internationally. The company was founded in 1941 and is headquartered in Seoul, South Korea.

CEO: Hee-Nam Choi37 employeesKRwww.ckd-holdings.com/company/summary.do

Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.

Browse More

Key metrics explained

Definitions, formulas, and how ValueMarkers calculates each indicator used in 001630.KS’s VM Score.

Explore More

Compare Competitors

Weekly Stock Analysis - Free

5 undervalued stocks, fully modeled. Every Monday. No spam.

Cookie Preferences

We use cookies to analyze site usage and improve your experience. You can accept all, reject all, or customize your preferences.